세계의 말단비대증 치료 시장 : 성장, 전망, 경쟁 분석(2024-2032년)

The acromegaly treatment market refers to the segment of the healthcare industry focused on the management and treatment of acromegaly, a rare hormonal disorder typically caused by an overproduction of growth hormone (GH), most often from a benign tumor on the pituitary gland. This condition is characterized by the enlargement of bones and tissues, which can lead to various complications and is usually a chronic disease requiring lifelong management. In brief, the acromegaly treatment market encompasses a range of therapeutic approaches, including surgery, medication, and radiation therapy. Surgical removal of the pituitary tumor is often the first line of treatment, aiming to reduce the levels of GH and alleviate symptoms. However, not all patients are suitable for surgery due to the size or location of the tumor, or other health concerns, necessitating alternative treatments. Drug therapies play a crucial role in the market and include somatostatin analogs (SSAs), GH receptor antagonists, and dopamine agonists. These medications aim to control hormone secretion, reduce tumor size, and manage symptoms. The acromegaly treatment market is estimated to grow at a CAGR of 5.5% from 2024 to 2032. The acromegaly treatment market is also influenced by ongoing research and development, aiming to find more effective and less invasive treatments. The rarity of the condition presents challenges in terms of market size and investment in research, but the significant impact of the disease on patients' quality of life continues to drive innovation and development in this field.

Advancements in Treatment and Diagnostic Techniques

A significant driver in the acromegaly treatment market is the advancements in treatment options and diagnostic techniques. Improved diagnostic methods, such as sophisticated imaging technologies and hormonal assays, have led to earlier and more accurate diagnosis of acromegaly, increasing the number of individuals seeking treatment. Advances in surgical techniques, including minimally invasive procedures like endoscopic transsphenoidal surgery, have improved success rates and reduced recovery times, making surgery a more viable option for many patients. Furthermore, developments in drug therapies, such as new somatostatin analogs and growth hormone receptor antagonists, offer better disease control with fewer side effects. These advancements not only improve patient outcomes but also drive market growth by increasing treatment options and enhancing the effectiveness of existing therapies.

Emerging Therapies and Personalized Medicine

An opportunity within the acromegaly treatment market lies in the development of emerging therapies and personalized medicine. The ongoing research into novel therapeutic agents, including new molecular targets and biologic drugs, holds the promise of more effective and tailored treatment options. Personalized medicine, focusing on genetic and molecular profiling, could lead to more individualized treatment plans, optimizing therapeutic effectiveness and minimizing adverse effects. This approach is particularly relevant in acromegaly, where patient responses to treatments can vary significantly. The potential of these emerging therapies and personalized approaches is significant, offering new avenues for growth and development in the market.

High Treatment Costs and Limited Accessibility

A major restraint in the acromegaly treatment market is the high cost of treatments and limited accessibility in certain regions. Acromegaly treatments, especially newer pharmaceuticals and advanced surgical techniques, can be prohibitively expensive, making them inaccessible to a portion of the patient population, particularly in low- and middle-income countries. The rarity of the condition also means that not all healthcare systems are equipped with the necessary expertise or facilities for treatment, leading to disparities in access to care. This issue is exacerbated by the chronic nature of acromegaly, which often requires lifelong treatment and monitoring, adding to the financial burden on patients and healthcare systems.

Challenges in Disease Management and Research

The acromegaly treatment market faces the challenge of effective disease management and research limitations. Managing acromegaly is complex, requiring a multidisciplinary approach due to its wide range of symptoms and potential complications. Continuous monitoring and adjustments in treatment are often necessary, posing a challenge for both patients and healthcare providers. Additionally, the rarity of acromegaly presents challenges in research, as limited patient populations can hinder large-scale clinical trials and studies, which are crucial for developing new treatments and understanding the disease better. This issue is a significant barrier to advancing treatment options and improving patient care in the acromegaly treatment market.

Market Segmentation by Drug Type

In the acromegaly treatment market, segmentation by drug type includes Somatostatin Analogs (SSAs), Growth Hormone Receptor Antagonists (GHRA), and others. SSAs hold the highest share of revenue within the market as of now. This dominance is due to their effectiveness in reducing growth hormone (GH) production and being the first-line treatment option for many patients. Somatostatin analogs, such as octreotide and lanreotide, have been widely used for several years, contributing to their substantial market share. In contrast, GHRA, represented mainly by pegvisomant, is expected to witness the highest Compound Annual Growth Rate (CAGR). This anticipated growth can be attributed to the drug's unique mechanism of action, which directly blocks GH receptors, thereby countering the effects of excess GH. This makes GHRA particularly effective for patients who do not respond adequately to SSAs. The increasing preference for targeted therapies in acromegaly treatment is likely to fuel the growth of the GHRA segment.

Market Segmentation by End-Use

Regarding market segmentation by end-use, Hospitals & Clinics and Others (which include homecare settings and research centers) are the primary categories. Hospitals and clinics currently generate the highest revenue in the acromegaly treatment market. This is because they are the main centers for both the diagnosis and treatment of acromegaly, offering comprehensive care that includes surgery, drug therapy, and regular monitoring. The expertise and advanced facilities available in hospitals and clinics make them the preferred choice for acromegaly treatment. However, the 'Others' segment is expected to grow at the highest CAGR. This growth can be attributed to the increasing adoption of homecare treatments and the development of long-acting drug formulations that can be administered outside of hospital settings. With advancements in telemedicine and home health care, patients are increasingly finding it feasible to manage their treatment regimens at home, thus driving growth in this segment. This trend towards convenient, patient-centric care models is anticipated to continue, further propelling the growth of this segment in the acromegaly treatment market.

Regional Insights

In the geographic analysis of the acromegaly treatment market, various trends are observed across different regions. As of 2023, North America held the highest revenue percentage, attributed to advanced healthcare infrastructure, high healthcare expenditure, and the presence of key market players. The region's dominance is also due to the higher awareness of rare diseases like acromegaly and better access to treatment options, including cutting-edge drug therapies and surgical interventions. From 2024 to 2032, the Asia-Pacific region is expected to exhibit the highest Compound Annual Growth Rate (CAGR). This growth projection is driven by increasing healthcare expenditure, improving healthcare infrastructure, and rising awareness of acromegaly in rapidly developing economies such as China and India. Additionally, the expanding presence of international pharmaceutical companies and increased investment in healthcare in these regions are factors contributing to this anticipated growth.

Competitive Landscape

In terms of competitive trends, the acromegaly treatment market is shaped by a number of key players and their strategic initiatives. As of 2023, companies like Novartis AG, Ipsen Pharma, SUN PHARMACEUTICAL INDUSTRIES LTD., Chiasma, Inc., Peptron, Inc., WOCKHARDT, Dauntless Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, Inc. dominated the market. These companies have employed strategies such as research and development of new drug formulations, collaborations for expanding drug portfolios, and efforts to improve drug accessibility globally. For instance, Novartis and Pfizer have been at the forefront in developing and marketing somatostatin analogs and growth hormone receptor antagonists, respectively.

Historical & Forecast Period

This study report represents an analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Acromegaly Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Acromegaly Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

• Somatostatin analogs
• GHRA
• Others

End-Use

• Hospitals & Clinics
• Others

Region Segment (2022-2032; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Acromegaly Treatment market?

What are the key investment pockets concerning product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2032.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Acromegaly Treatment market?

Which is the largest regional market for Acromegaly Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Acromegaly Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Acromegaly Treatment market worldwide?

Table of Contents

1. Preface

• 1.1. Report Description
  • 1.1.1. Purpose of the Report
  • 1.1.2. Target Audience
  • 1.1.3. Key Offerings
• 1.2. Market Segmentation
• 1.3. Research Methodology
  • 1.3.1. Phase I - Secondary Research
  • 1.3.2. Phase II - Primary Research
  • 1.3.3. Phase III - Expert Panel Review
  • 1.3.4. Assumptions
  • 1.3.5. Approach Adopted

2. Executive Summary

• 2.1. Market Snapshot: Global Acromegaly Treatment Market
• 2.2. Global Acromegaly Treatment Market, By Drug Type, 2023 (US$ Million)
• 2.3. Global Acromegaly Treatment Market, By End-Use, 2023 (US$ Million)
• 2.4. Global Acromegaly Treatment Market, By Geography, 2023 (US$ Million)
• 2.5. Attractive Investment Proposition by Geography, 2023

3. Acromegaly Treatment Market: Competitive Analysis

• 3.1. Market Positioning of Key Acromegaly Treatment Market Vendors
• 3.2. Strategies Adopted by Acromegaly Treatment Market Vendors
• 3.3. Key Industry Strategies
• 3.4. Tier Analysis 2023 Versus 2032

4. Acromegaly Treatment Market: Macro Analysis & Market Dynamics

• 4.1. Introduction
• 4.2. Global Acromegaly Treatment Market Value, 2022 - 2032, (US$ Million)
• 4.3. Market Dynamics
  • 4.3.1. Market Drivers
  • 4.3.2. Market Restraints
  • 4.3.3. Key Challenges
  • 4.3.4. Key Opportunities
• 4.4. Impact Analysis of Drivers and Restraints
• 4.5. See-Saw Analysis
• 4.6. Porter's Five Force Model
  • 4.6.1. Supplier Power
  • 4.6.2. Buyer Power
  • 4.6.3. Threat Of Substitutes
  • 4.6.4. Threat Of New Entrants
  • 4.6.5. Competitive Rivalry
• 4.7. PESTEL Analysis
  • 4.7.1. Political Landscape
  • 4.7.2. Economic Landscape
  • 4.7.3. Technology Landscape
  • 4.7.4. Legal Landscape
  • 4.7.5. Social Landscape

5. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)

• 5.1. Market Overview
• 5.2. Growth & Revenue Analysis: 2023 Versus 2032
• 5.3. Market Segmentation
  • 5.3.1. Somatostatin analogs
  • 5.3.2. GHRA
  • 5.3.3. Others

6. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)

• 6.1. Market Overview
• 6.2. Growth & Revenue Analysis: 2023 Versus 2032
• 6.3. Market Segmentation
  • 6.3.1. Hospitals & Clinics
  • 6.3.2. Others

7. North America Acromegaly Treatment Market, 2022-2032, USD (Million)

• 7.1. Market Overview
• 7.2. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
• 7.3. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
• 7.4.Acromegaly Treatment Market: By Region, 2022-2032, USD (Million)
  • 7.4.1.North America
    • 7.4.1.1. U.S.
      • 7.4.1.1.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 7.4.1.1.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 7.4.1.2. Canada
      • 7.4.1.2.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 7.4.1.2.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 7.4.1.3. Rest of North America
      • 7.4.1.3.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 7.4.1.3.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)

8. UK and European Union Acromegaly Treatment Market, 2022-2032, USD (Million)

• 8.1. Market Overview
• 8.2. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
• 8.3. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
• 8.4.Acromegaly Treatment Market: By Region, 2022-2032, USD (Million)
  • 8.4.1.UK and European Union
    • 8.4.1.1. UK
      • 8.4.1.1.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 8.4.1.1.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 8.4.1.2. Germany
      • 8.4.1.2.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 8.4.1.2.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 8.4.1.3. Spain
      • 8.4.1.3.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 8.4.1.3.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 8.4.1.4. Italy
      • 8.4.1.4.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 8.4.1.4.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 8.4.1.5. France
      • 8.4.1.5.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 8.4.1.5.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 8.4.1.6. Rest of Europe
      • 8.4.1.6.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 8.4.1.6.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)

9. Asia Pacific Acromegaly Treatment Market, 2022-2032, USD (Million)

• 9.1. Market Overview
• 9.2. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
• 9.3. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
• 9.4.Acromegaly Treatment Market: By Region, 2022-2032, USD (Million)
  • 9.4.1.Asia Pacific
    • 9.4.1.1. China
      • 9.4.1.1.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 9.4.1.1.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 9.4.1.2. Japan
      • 9.4.1.2.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 9.4.1.2.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 9.4.1.3. India
      • 9.4.1.3.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 9.4.1.3.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 9.4.1.4. Australia
      • 9.4.1.4.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 9.4.1.4.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 9.4.1.5. South Korea
      • 9.4.1.5.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 9.4.1.5.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 9.4.1.6. Rest of Asia Pacific
      • 9.4.1.6.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 9.4.1.6.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)

10. Latin America Acromegaly Treatment Market, 2022-2032, USD (Million)

• 10.1. Market Overview
• 10.2. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
• 10.3. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
• 10.4.Acromegaly Treatment Market: By Region, 2022-2032, USD (Million)
  • 10.4.1.Latin America
    • 10.4.1.1. Brazil
      • 10.4.1.1.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 10.4.1.1.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 10.4.1.2. Mexico
      • 10.4.1.2.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 10.4.1.2.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 10.4.1.3. Rest of Latin America
      • 10.4.1.3.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 10.4.1.3.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)

11. Middle East and Africa Acromegaly Treatment Market, 2022-2032, USD (Million)

• 11.1. Market Overview
• 11.2. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
• 11.3. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
• 11.4.Acromegaly Treatment Market: By Region, 2022-2032, USD (Million)
  • 11.4.1.Middle East and Africa
    • 11.4.1.1. GCC
      • 11.4.1.1.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 11.4.1.1.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 11.4.1.2. Africa
      • 11.4.1.2.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 11.4.1.2.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)
    • 11.4.1.3. Rest of Middle East and Africa
      • 11.4.1.3.1. Acromegaly Treatment Market: By Drug Type, 2022-2032, USD (Million)
      • 11.4.1.3.2. Acromegaly Treatment Market: By End-Use, 2022-2032, USD (Million)

12. Company Profile

• 12.1. Novartis AG
  • 12.1.1. Company Overview
  • 12.1.2. Financial Performance
  • 12.1.3. Product Portfolio
  • 12.1.4. Strategic Initiatives
• 12.2. Ipsen Pharma
  • 12.2.1. Company Overview
  • 12.2.2. Financial Performance
  • 12.2.3. Product Portfolio
  • 12.2.4. Strategic Initiatives
• 12.3. SUN PHARMACEUTICAL INDUSTRIES LTD.
  • 12.3.1. Company Overview
  • 12.3.2. Financial Performance
  • 12.3.3. Product Portfolio
  • 12.3.4. Strategic Initiatives
• 12.4. Chiasma, Inc.
  • 12.4.1. Company Overview
  • 12.4.2. Financial Performance
  • 12.4.3. Product Portfolio
  • 12.4.4. Strategic Initiatives
• 12.5. Peptron, Inc.
  • 12.5.1. Company Overview
  • 12.5.2. Financial Performance
  • 12.5.3. Product Portfolio
  • 12.5.4. Strategic Initiatives
• 12.6. WOCKHARDT
  • 12.6.1. Company Overview
  • 12.6.2. Financial Performance
  • 12.6.3. Product Portfolio
  • 12.6.4. Strategic Initiatives
• 12.7. Dauntless Pharmaceuticals
  • 12.7.1. Company Overview
  • 12.7.2. Financial Performance
  • 12.7.3. Product Portfolio
  • 12.7.4. Strategic Initiatives
• 12.8. Pfizer Inc.
  • 12.8.1. Company Overview
  • 12.8.2. Financial Performance
  • 12.8.3. Product Portfolio
  • 12.8.4. Strategic Initiatives
• 12.9. Ionis Pharmaceuticals, Inc.
  • 12.9.1. Company Overview
  • 12.9.2. Financial Performance
  • 12.9.3. Product Portfolio
  • 12.9.4. Strategic Initiatives
• 12.10. Other Notable Players
  • 12.10.1. Company Overview
  • 12.10.2. Financial Performance
  • 12.10.3. Product Portfolio
  • 12.10.4. Strategic Initiatives